Virtus Investment Advisers’s Centessa Pharmaceuticals CNTA Stock Holding History

Virtus Investment Advisers’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,286	Closed	-$409K	–	471
2026 Q1	$409K	Buy	10,286 +252	+3%	+$6.45K	0.11%	244
2025 Q4	$251K	Buy	10,034 +583	+6%	+$14.8K	0.07%	329
2025 Q3	$229K	Buy	9,451 +1,641	+21%	+$29.2K	0.07%	249
2025 Q2	$103K	Sell	7,810 -1,923	-20%	-$24.4K	0.03%	326
2025 Q1	$140K	Buy	+9,733	New	+$159K	0.04%	353

Virtus Investment Advisers's CNTA Position: Q2 2026 in Review

Virtus Investment Advisers sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 10,286 shares — an estimated $409K sold.

Virtus Investment Advisers first reported a position in CNTA in Q1 2025 and held it in 5 quarters. The position peaked at $409K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Virtus Investment Advisers reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Virtus Investment Advisers sold 10,286 Centessa Pharmaceuticals shares in Q2 2026, an estimated $409K.
Virtus Investment Advisers first reported a position in Centessa Pharmaceuticals in Q1 2025 and held it in 5 quarters.
Virtus Investment Advisers's Centessa Pharmaceuticals position peaked at $409K in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.